Latest Recursion News & Updates

See the latest news and media coverage for Recursion. We track all announcements, press releases, and industry mentions in real time, all in one place.

Recursion

Clinical-stage biotechnology company using AI to discover medicines

recursion.com

Headquarters: Salt Lake City, United States
Founded year: 2013
Company type: Public company
Number of employees: 760–1,000
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Recursion

In short: Recursion priced a $200 million offering, advanced pipeline programs, and progressed its Genentech neuroscience collaboration.

Company announcements

October 26 Recursion

Recursion hosts webinar on updated REC-4881 data

The company releases Q3 2026 financial results on November 2. The webinar features CEO Najat Khan and expert panels discussing Familial Adenomatous Polyposis treatments.

October 15 Recursion

Recursion announces $200M offering and pipeline updates

The company raised capital via an oversubscribed follow-on offering. It reported durable polyp reductions for REC-4881 in FAP, partial responses for REC-1245 in cancer, and a Sanofi partnership milestone.

August 5 Recursion

Recursion and Genentech advance first neuroscience target into program

The target passed pathway, functional, and disease validation from an AI-driven neuron map built from over 1 trillion cells; it now enters small molecule hit generation.

April 29 Recursion

Recursion to report Q1 2026 results on May 6

Company will host earnings call at 8:00 am ET with webcast and public Q&A.

Media coverage

Yesterday StocksToTrade

RXRX Stock Jumps As Sanofi Deal And Trial Data Ignite AI Drug Story

Recursion Pharmaceuticals Inc. stocks have been trading up by 7.04 percent following upbeat coverage of its AI-driven drug discovery advancements. Key Takeaways Traders Are Watching...

October 15 Yahoo Finance

Recursion Prices $200 Million Stock Offering, Sanofi Options Drug Candidate

Prices displayed are informational. Learn more Recursion Pharmaceuticals (RXRX) said Thursday it priced an offering of 61.5 million shares at $3.25 each to raise gross...

October 15 MarketScreener

Recursion Pharmaceuticals, Inc. Reports Phase 1b/2 Data For REC-4881 In Familial Adenomatous Polyposis And Phase 1 Data For REC-1245

Most patients (21 of 26; 80.8%) had TRAEs of Grade 2 or lower, consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and...

October 15 The Star

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically...

Never miss news about Recursion

Track Recursion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Recursion competitors & trending companies

Browse news for competitors to Recursion and other trending companies.